Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14225101 | 0.83 | PDE2A (0.43) | PDE2APDE10ASMN1; SMN2CYP11B2CYP11B1 | |
| SCHEMBL10175358 | 0.82 | PDE10A (0.65) | PDE2APDE10ASMN1; SMN2CYP11B2CYP11B1 | |
| SCHEMBL1769839 | 0.82 | PDE2A (0.43) | PDE2APDE10ASMN1; SMN2CYP11B2CYP11B1 | |
| SCHEMBL10175361 | 0.80 | PDE2A (0.52) | PDE2APDE10ASMN1; SMN2CYP11B2CYP11B1 | |
| SCHEMBL14152407 | 0.80 | PDE2A (0.47) | PDE2APDE10ASMN1; SMN2CYP11B2CYP11B1 | |
| SCHEMBL1769942 | 0.78 | PDE2A (0.48) | PDE2APDE10ASMN1; SMN2CYP11B2CYP11B1 | |
| SCHEMBL17896693 | 0.78 | PDE10A (0.50) | PDE2APDE10ASMN1; SMN2CYP11B2CYP11B1 | |
| SCHEMBL10175364 | 0.77 | L3MBTL1 (0.48) | PDE2APDE10ASMN1; SMN2CYP11B2CYP11B1 | |
| SCHEMBL10175359 | 0.74 | MEN1 (0.62) | PDE2APDE10ASMN1; SMN2CYP11B2CYP11B1 | |
| SCHEMBL17896690 | 0.73 | CYP11B2 (0.46) | PDE2APDE10ASMN1; SMN2CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2993169-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2017-12-20 | — | — | EP | claimed |
| EP-2993169-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| EP-2993169-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| EP-2993169-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-2501678-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| WO-2011061168-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | PDE2A 155/4885PDE10A 250/4885SMN1; SMN2 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.